{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-033148","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2024-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.686696+00:00","generated_at":"2026-06-04T13:22:09.252747+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Axsome doses first patient in PARADIGM Phase 3 trial of solriamfetol for MDD","bullets":["First patient dosed in Phase 3 PARADIGM trial of solriamfetol for major depressive disorder.","Randomized, double-blind, placebo-controlled trial with ~300 patients (1:1 ratio, 300 mg or placebo for 6 weeks).","Primary endpoint is change in Montgomery-Åsberg Depression Rating Scale (MADRS).","Solriamfetol is an investigational treatment; Axsome specializes in CNS disorders."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-033148","json":"https://secwatch.observer/filing/0000950170-24-033148.json","markdown":"https://secwatch.observer/filing/0000950170-24-033148.md","text":"https://secwatch.observer/filing/0000950170-24-033148.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024033148/0000950170-24-033148-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024033148/axsm-20240319.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T13:22:09.252747+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}